Literature DB >> 14585940

Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma.

Trisha M Shattuck1, Stiina Välimäki, Takao Obara, Randall D Gaz, Orlo H Clark, Dolores Shoback, Margaret E Wierman, Katsuyoshi Tojo, Christiane M Robbins, John D Carpten, Lars-Ove Farnebo, Catharina Larsson, Andrew Arnold.   

Abstract

BACKGROUND: We looked for mutations of the HRPT2 gene, which encodes the parafibromin protein, in sporadic parathyroid carcinoma because germ-line inactivating HRPT2 mutations have been found in a type of familial hyperparathyroidism--hyperparathyroidism-jaw tumor (HPT-JT) syndrome--that carries an increased risk of parathyroid cancer.
METHODS: We directly sequenced the full coding and flanking splice-junctional regions of the HRPT2 gene in 21 parathyroid carcinomas from 15 patients who had no known family history of primary hyperparathyroidism or the HPT-JT syndrome at presentation. We also sought to confirm the somatic nature of the identified mutations and tested the carcinomas for tumor-specific loss of heterozygosity at HRPT2.
RESULTS: Parathyroid carcinomas from 10 of the 15 patients had HRPT2 mutations, all of which were predicted to inactivate the encoded parafibromin protein. Two distinct HRPT2 mutations were found in tumors from five patients, and biallelic inactivation as a result of a mutation and loss of heterozygosity was found in one tumor. At least one HRPT2 mutation was demonstrably somatic in carcinomas from six patients. Unexpectedly, HRPT2 mutations in the parathyroid carcinomas of three patients were identified as germ-line mutations.
CONCLUSIONS: Sporadic parathyroid carcinomas frequently have HRPT2 mutations that are likely to be of pathogenetic importance. Certain patients with apparently sporadic parathyroid carcinoma carry germ-line mutations in HRPT2 and may have the HPT-JT syndrome or a phenotypic variant. Copyright 2003 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14585940     DOI: 10.1056/NEJMoa031237

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  146 in total

1.  Clinical assessment incorporating a personal genome.

Authors:  Euan A Ashley; Atul J Butte; Matthew T Wheeler; Rong Chen; Teri E Klein; Frederick E Dewey; Joel T Dudley; Kelly E Ormond; Aleksandra Pavlovic; Alexander A Morgan; Dmitry Pushkarev; Norma F Neff; Louanne Hudgins; Li Gong; Laura M Hodges; Dorit S Berlin; Caroline F Thorn; Katrin Sangkuhl; Joan M Hebert; Mark Woon; Hersh Sagreiya; Ryan Whaley; Joshua W Knowles; Michael F Chou; Joseph V Thakuria; Abraham M Rosenbaum; Alexander Wait Zaranek; George M Church; Henry T Greely; Stephen R Quake; Russ B Altman
Journal:  Lancet       Date:  2010-05-01       Impact factor: 79.321

Review 2.  Hypercalcemia in children and adolescents.

Authors:  Steven A Lietman; Emily L Germain-Lee; Michael A Levine
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

Review 3.  Parathyroid cancer.

Authors:  Fiona McClenaghan; Yassar A Qureshi
Journal:  Gland Surg       Date:  2015-08

4.  Cytoplasmic polyadenylation element binding protein is a conserved target of tumor suppressor HRPT2/CDC73.

Authors:  J-H Zhang; L M Panicker; E M Seigneur; L Lin; C D House; W Morgan; W C Chen; H Mehta; M Haj-Ali; Z-X Yu; W F Simonds
Journal:  Cell Death Differ       Date:  2010-03-26       Impact factor: 15.828

5.  Synchronous parathyroid carcinoma, parathyroid adenoma, and papillary thyroid carcinoma in a patient with severe and long-standing hyperparathyroidism.

Authors:  Melanie Goldfarb; Patrick O'Neal; Judy L Shih; Pamela Hartzband; James Connolly; Per-Olof Hasselgren
Journal:  Endocr Pract       Date:  2009 Jul-Aug       Impact factor: 3.443

Review 6.  Translational research in endocrine surgery.

Authors:  Scott K Sherman; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

7.  Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics.

Authors:  D Scarpelli; L D'Aloiso; F Arturi; A Scillitani; I Presta; M Bisceglia; C Cristofaro; D Russo; S Filetti
Journal:  J Endocrinol Invest       Date:  2004-12       Impact factor: 4.256

Review 8.  Primary hyperparathyroidism.

Authors:  John P Bilezikian; Natalie E Cusano; Aliya A Khan; Jian-Min Liu; Claudio Marcocci; Francisco Bandeira
Journal:  Nat Rev Dis Primers       Date:  2016-05-19       Impact factor: 52.329

Review 9.  Parathyroid carcinoma: current understanding and new insights into gene expression and intraoperative parathyroid hormone kinetics.

Authors:  Mohamed Abdelgadir Adam; Brian R Untch; John A Olson
Journal:  Oncologist       Date:  2010-01-05

10.  The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene.

Authors:  Ling Lin; Jian-Hua Zhang; Leelamma M Panicker; William F Simonds
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.